The hot area of antibody-drug conjugates (ADCs) is getting a new player with the launch of Pheon Therapeutics, a UK-based biotech that comes armed with a sizeable cash pile and a hugely experienced senior management team.
Pheon has emerged after closing a $68m series A financing in March that was led by Brandon Capital, Forbion and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?